MedTrace Logo

Investigating the Effects of Cannabidiol on Social Anxiety Disorder

NCT05649059 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-03

No results posted yet for this study

Summary

The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).

Conditions

  • Phobia, Social

Interventions

DRUG

Cannabidiol

Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.

DRUG

Placebo

Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.

Sponsors & Collaborators

Principal Investigators

  • John Gabrieli, PhD · Massachusetts Institute of Technology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2026-05-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649059 on ClinicalTrials.gov